TSX runs higher on rate cut expectations
Nuvalent , Inc. (NASDAQ:NUVL), a $5.6 billion market cap biotech company, saw Chief Development Officer Darlene Noci sell 4,000 shares of Class A Common Stock on July 30, 2025, for a total of $321,440. The sales were executed at a weighted average price of $80.36, with individual prices ranging from $79.98 to $80.92. According to InvestingPro data, analysts maintain price targets between $100-$140, suggesting potential upside from current levels.
On the same day, Noci also exercised options to acquire 4,000 shares of Class A Common Stock at a price of $27.85, totaling $111,400.
These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 18, 2024. Following these transactions, Noci directly owns 48,034 shares of Nuvalent, Inc.
In other recent news, Nuvalent, Inc. has commenced its Phase 3 ALKAZAR clinical trial, evaluating neladalkib for advanced ALK-positive non-small cell lung cancer. This trial will compare neladalkib to alectinib, a current standard of care, and has already dosed its first patient. The study aims to enroll approximately 450 patients. Additionally, Nuvalent is planning a rolling New Drug Application submission for its ROS1-selective inhibitor, zidesamtinib, in July 2025, with the process expected to complete by the third quarter of that year. This follows positive pivotal data in previously treated ROS1-positive NSCLC patients. In terms of analyst coverage, Goldman Sachs initiated coverage on Nuvalent with a Buy rating and a price target of $105, citing the efficacy and safety profile of zidesamtinib. UBS also raised its price target for Nuvalent to $114, maintaining a Buy rating, after the release of pivotal Phase 2 data for zidesamtinib. These developments reflect growing interest in Nuvalent’s pipeline and its potential impact on lung cancer treatment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.